Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks

Abstract

Background

Available network meta-analyses (NMAs) comparing the efficacy of biologics in nail psoriasis (NP) have not included recently approved biologics such as bimekizumab nor have they provided comparisons up to 1 year.

Objective

We conducted two NMAs that update and extend results from a previous NMA comparing biologics for achieving complete resolution of NP.

Methods

Bayesian NMAs were performed using a generalized linear model with a logit link to model the binary outcome of nail clearance at weeks 24–28 and 48–52.

Results

For the NMA at weeks 24–28, which included seven biologics and placebo, the absolute probability of achieving complete resolution of NP was highest for ixekizumab (46.4%; 95% credibility interval [CrI] 35.2–58.0), followed by brodalumab (37.1%; 95% CrI 17.1–62.2) and bimekizumab (30.3%; 95% CrI 12.7–53.9). For the NMA at weeks 48–52, which included six biologics, the absolute probability was highest for ixekizumab (77.2%; 95% CrI 51.1–93.4), followed by adalimumab (75.6%; 95% CrI 61.5–87.3) and brodalumab (71.9%; 95% CrI 38.4–93.2).

Conclusion

Among biologics included in these two NMAs, ixekizumab has the highest absolute probability of achieving complete resolution of NP. Results may help to inform treatment decisions for patients with NP.

Keywords:

• Nail psoriasis
• network meta-analysis
• biologics
• Nail Psoriasis Severity Index (NAPSI)
• Physician’s Global Assessment of Fingernails (PGA-F)
• complete clearance/resolution of nail psoriasis
• ixekizumab

Acknowledgments

The authors would like to acknowledge Greg Plosker (Rx Communications, Mold, UK) for medical writing assistance with the preparation of this manuscript. Statistical analysis support for the study was also provided by Christophe Sapin, Michael Sonksen and Alan Brnabic (Eli Lilly and Company).

Disclosure statement

A. Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, Boehringer Ingelheim, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from Amgen, AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, McNeil Consumer Healthcare, Horizon Therapeutics, Boehringer Ingelheim, and Janssen Pharmaceuticals. Lars Erik Kristensen has received speaker & consultancy fees from AbbVie, Amgen, UCB, Galapagos, Novartis, Eli Lilly, Pfizer, Janssen Pharmaceutical, Zuellig Pharma. And IIT grants from AbbVie, UCB, Novartis, Eli Lilly, Pfizer. Luis Puig has received consultancy/speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Fresenius-Kabi, Janssen, JS Biocad, Leo-Pharma, Lilly, Novartis, Pfizer, Samsung-Bioepis, and UCB. Phoebe Rich has received research grants as a principal investigator on pharmaceutical trials from AbbVie, Arcutis, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Sun Pharma, and UCB. Saxon D. Smith has served as an investigator, speaker, and/or advisor for AbbVie, Sanofi Aventis, Eli Lilly, Novartis, UCB, Regeneron, BMS, Pfizer, Sanofi Genzyme, Leo Pharma, Merck Sharp & Dohme Corp, Amgen, Janssen Cilag, Johnson and Johnson. Alyssa Garrelts, Kyoungah See, Thorsten Holzkaemper, Konstantinos Fotiou, Christopher Schuster are employees and minor stockholders of Eli Lilly and Company.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Additional information

Funding

This study was funded by Eli Lilly and Company.